Cargando…

32.4 ALTERED COMPLEMENT PATHWAY PROTEIN EXPRESSION IS ASSOCIATED WITH PSYCHOTIC EXPERIENCES AT AGE 11 WHICH PERSIST AT AGE 18

BACKGROUND: The identification of early biomarkers of psychotic disorder is important because early treatment is associated with improved outcome. We have previously shown that altered complement and coagulation pathway associated proteins are associated pathway with psychotic disorder at age 18. In...

Descripción completa

Detalles Bibliográficos
Autores principales: Cotter, David, English, Jane, Foecking, Melanie, Cannon, Mary, Rutten, Bart, Zammit, Stanley, Lewis, Glyn, Sabhwerwal, Sophie, Lopez, Lorna, O’Gorman, Aoife, Cagney, Gerard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888552/
http://dx.doi.org/10.1093/schbul/sby014.135
_version_ 1783312549026988032
author Cotter, David
English, Jane
Foecking, Melanie
Cannon, Mary
Rutten, Bart
Zammit, Stanley
Lewis, Glyn
Sabhwerwal, Sophie
Lopez, Lorna
O’Gorman, Aoife
Cagney, Gerard
author_facet Cotter, David
English, Jane
Foecking, Melanie
Cannon, Mary
Rutten, Bart
Zammit, Stanley
Lewis, Glyn
Sabhwerwal, Sophie
Lopez, Lorna
O’Gorman, Aoife
Cagney, Gerard
author_sort Cotter, David
collection PubMed
description BACKGROUND: The identification of early biomarkers of psychotic disorder is important because early treatment is associated with improved outcome. We have previously shown that altered complement and coagulation pathway associated proteins are associated pathway with psychotic disorder at age 18. In the current study we test the hypothesis that altered complement pathway proteins are associated with persisting psychotic experiences from age 11 to age 18. METHODS: The Avon Longitudinal Study of Parents and Children (ALSPAC) is a prospective general population cohort, and a rich resource of demographic, environmental, and clinical data on the individuals involved. We studied a subsample of the cohort who participated in psychiatric assessment interviews at age 11 and 18, and who provided plasma samples at age 11. Semi-targeted proteomic profiling was used to specifically assess the complement pathway proteins in age 11 children who experienced psychotic experiences (but not disorder) at age 11 and age 18 (n=39) compared to age 11 children who only experienced psychotic experiences at age 11. RESULTS: 11 of 34 proteins assessed were significantly differentially expressed at p<0.05 and of these 8 remained significant following correction for multiple comparisons. Protein changes were in keeping with increased proteins expression of most complement pathway proteins. Several protein changes represented specific replications of the changes observed in age 11 samples prior to psychotic disorder at age 18, namely increased plasminogen, complement factor H, and complement factor 1r. DISCUSSION: Our findings implicate the blood complement system in the persistence of psychotic experiences from age 11 to age 18. Considering that psychotic experiences are predictive of many psychiatric disorders our findings implicate the complement system not just in psychotic disorders, but more broadly in the vulnerability to a range of adult psychiatric disorders.
format Online
Article
Text
id pubmed-5888552
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-58885522018-04-11 32.4 ALTERED COMPLEMENT PATHWAY PROTEIN EXPRESSION IS ASSOCIATED WITH PSYCHOTIC EXPERIENCES AT AGE 11 WHICH PERSIST AT AGE 18 Cotter, David English, Jane Foecking, Melanie Cannon, Mary Rutten, Bart Zammit, Stanley Lewis, Glyn Sabhwerwal, Sophie Lopez, Lorna O’Gorman, Aoife Cagney, Gerard Schizophr Bull Abstracts BACKGROUND: The identification of early biomarkers of psychotic disorder is important because early treatment is associated with improved outcome. We have previously shown that altered complement and coagulation pathway associated proteins are associated pathway with psychotic disorder at age 18. In the current study we test the hypothesis that altered complement pathway proteins are associated with persisting psychotic experiences from age 11 to age 18. METHODS: The Avon Longitudinal Study of Parents and Children (ALSPAC) is a prospective general population cohort, and a rich resource of demographic, environmental, and clinical data on the individuals involved. We studied a subsample of the cohort who participated in psychiatric assessment interviews at age 11 and 18, and who provided plasma samples at age 11. Semi-targeted proteomic profiling was used to specifically assess the complement pathway proteins in age 11 children who experienced psychotic experiences (but not disorder) at age 11 and age 18 (n=39) compared to age 11 children who only experienced psychotic experiences at age 11. RESULTS: 11 of 34 proteins assessed were significantly differentially expressed at p<0.05 and of these 8 remained significant following correction for multiple comparisons. Protein changes were in keeping with increased proteins expression of most complement pathway proteins. Several protein changes represented specific replications of the changes observed in age 11 samples prior to psychotic disorder at age 18, namely increased plasminogen, complement factor H, and complement factor 1r. DISCUSSION: Our findings implicate the blood complement system in the persistence of psychotic experiences from age 11 to age 18. Considering that psychotic experiences are predictive of many psychiatric disorders our findings implicate the complement system not just in psychotic disorders, but more broadly in the vulnerability to a range of adult psychiatric disorders. Oxford University Press 2018-04 2018-04-01 /pmc/articles/PMC5888552/ http://dx.doi.org/10.1093/schbul/sby014.135 Text en © Maryland Psychiatric Research Center 2018. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstracts
Cotter, David
English, Jane
Foecking, Melanie
Cannon, Mary
Rutten, Bart
Zammit, Stanley
Lewis, Glyn
Sabhwerwal, Sophie
Lopez, Lorna
O’Gorman, Aoife
Cagney, Gerard
32.4 ALTERED COMPLEMENT PATHWAY PROTEIN EXPRESSION IS ASSOCIATED WITH PSYCHOTIC EXPERIENCES AT AGE 11 WHICH PERSIST AT AGE 18
title 32.4 ALTERED COMPLEMENT PATHWAY PROTEIN EXPRESSION IS ASSOCIATED WITH PSYCHOTIC EXPERIENCES AT AGE 11 WHICH PERSIST AT AGE 18
title_full 32.4 ALTERED COMPLEMENT PATHWAY PROTEIN EXPRESSION IS ASSOCIATED WITH PSYCHOTIC EXPERIENCES AT AGE 11 WHICH PERSIST AT AGE 18
title_fullStr 32.4 ALTERED COMPLEMENT PATHWAY PROTEIN EXPRESSION IS ASSOCIATED WITH PSYCHOTIC EXPERIENCES AT AGE 11 WHICH PERSIST AT AGE 18
title_full_unstemmed 32.4 ALTERED COMPLEMENT PATHWAY PROTEIN EXPRESSION IS ASSOCIATED WITH PSYCHOTIC EXPERIENCES AT AGE 11 WHICH PERSIST AT AGE 18
title_short 32.4 ALTERED COMPLEMENT PATHWAY PROTEIN EXPRESSION IS ASSOCIATED WITH PSYCHOTIC EXPERIENCES AT AGE 11 WHICH PERSIST AT AGE 18
title_sort 32.4 altered complement pathway protein expression is associated with psychotic experiences at age 11 which persist at age 18
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888552/
http://dx.doi.org/10.1093/schbul/sby014.135
work_keys_str_mv AT cotterdavid 324alteredcomplementpathwayproteinexpressionisassociatedwithpsychoticexperiencesatage11whichpersistatage18
AT englishjane 324alteredcomplementpathwayproteinexpressionisassociatedwithpsychoticexperiencesatage11whichpersistatage18
AT foeckingmelanie 324alteredcomplementpathwayproteinexpressionisassociatedwithpsychoticexperiencesatage11whichpersistatage18
AT cannonmary 324alteredcomplementpathwayproteinexpressionisassociatedwithpsychoticexperiencesatage11whichpersistatage18
AT ruttenbart 324alteredcomplementpathwayproteinexpressionisassociatedwithpsychoticexperiencesatage11whichpersistatage18
AT zammitstanley 324alteredcomplementpathwayproteinexpressionisassociatedwithpsychoticexperiencesatage11whichpersistatage18
AT lewisglyn 324alteredcomplementpathwayproteinexpressionisassociatedwithpsychoticexperiencesatage11whichpersistatage18
AT sabhwerwalsophie 324alteredcomplementpathwayproteinexpressionisassociatedwithpsychoticexperiencesatage11whichpersistatage18
AT lopezlorna 324alteredcomplementpathwayproteinexpressionisassociatedwithpsychoticexperiencesatage11whichpersistatage18
AT ogormanaoife 324alteredcomplementpathwayproteinexpressionisassociatedwithpsychoticexperiencesatage11whichpersistatage18
AT cagneygerard 324alteredcomplementpathwayproteinexpressionisassociatedwithpsychoticexperiencesatage11whichpersistatage18